<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>64</patient-age><report-id>PHHY2012JP102117</report-id><gender>female</gender><reactions><reaction>Hepatic function disorder</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOMETA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>FEMARA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Metastases to bone</indication><indication>Breast cancer</indication></indications><patient-age>64</patient-age><outcomes/><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053177_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134155</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012JP102117</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-10-31</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012JP102117</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>JP</reportercountry>
			<qualification code="2">Pharmacist</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>64</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Breast cancer</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Hepatic function disorder</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hepatic function disorder</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hepatic function abnormal</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Alanine aminotransferase</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Alanine aminotransferase</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Alanine aminotransferase</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform normalized="solution for infusion">Solution For Infusion</drugdosageform>
				<drugadministrationroute code="041">Intravenous drip</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Metastases to bone</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-10-10</drugstartdate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic function abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic function abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform normalized="solution for infusion">Solution For Infusion</drugdosageform>
				<drugadministrationroute code="041">Intravenous drip</drugadministrationroute>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic function abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic function abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>FEMARA</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Breast cancer</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LETROZOLE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic function abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hepatic function abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012JP102117, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacist </Semaphore>on 31 Oct 2012 with a follow up report received from a <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacist </Semaphore>on 06 Dec 2012. This case refers to a 64-year old female patient. The patient received <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa </Semaphore>(<Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.49" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore></Semaphore>hydrate) for <Semaphore x="3107270" class="MedDRA LLT" value="Metastases to breast" score="1.00" ID="10027454"><Semaphore x="3107270" class="MedDRA LLT" value="Metastases to breast" score="1.00" ID="10027454"><Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastases </Semaphore><Semaphore x="1637909" class="Disease or Finding" value="Breast Carcinoma" score="1.00" ID="C4872">of <Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore></Semaphore>
      <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016">
       <Semaphore x="1637909" class="Disease or Finding" value="Breast Carcinoma" score="1.00" ID="C4872">
        </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016">
      <Semaphore x="1637909" class="Disease or Finding" value="Breast Carcinoma" score="1.00" ID="C4872">
       <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016">cancer </Semaphore>
       <Semaphore x="2822315" class="MedDRA LLT" value="Bone neoplasm malignant" score="1.00" ID="10053650">
        </Semaphore></Semaphore>
      <Semaphore x="2822315" class="MedDRA LLT" value="Bone neoplasm malignant" score="1.00" ID="10053650">
       <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016">to </Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="2152114" class="Disease or Finding" value="Malignant Bone Neoplasm" score="1.00" ID="C4016">
     <Semaphore x="2822315" class="MedDRA LLT" value="Bone neoplasm malignant" score="1.00" ID="10053650">
      <Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">bone </Semaphore></Semaphore></Semaphore>every three weeks from 10 Oct 2012 at an unknown dose, and <Semaphore x="565378" class="Medicine" value="Femara" score="0.87" ID="241615">Femara </Semaphore>(<Semaphore x="778363" class="Medicine" value="letrozole" score="0.49" ID="281905">letrozole</Semaphore>) for <Semaphore x="2826913" class="MedDRA LLT" value="Breast cancer" score="1.00" ID="10006187"><Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore>cancer</Semaphore>. On an unspecified date, the patient temporarily developed <Semaphore x="2117785" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Disorder" score="1.00" ID="C3196">hepatic function disorder</Semaphore>. On an unspecified date, <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was suspended. Although <Semaphore x="2117785" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Disorder" score="1.00" ID="C3196">hepatic function disorder </Semaphore>once became stable, hepatic function values were increasing even after discontinuation of <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>. On the third week after administration of <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa</Semaphore>, <Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">alanine aminotransferase </Semaphore>(<Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">ALT</Semaphore>) <Semaphore x="779631" class="Medicine" value="Level" score="0.87" ID="187620">level </Semaphore>was 400. Thereafter, as <Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">ALT </Semaphore><Semaphore x="779631" class="Medicine" value="Level" score="0.87" ID="187620">level </Semaphore>improved to 150, <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa </Semaphore>was re administered. One week after administration of <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa</Semaphore>, <Semaphore x="2725714" class="MedDRA LLT" value="Alanine aminotransferase increased" score="1.00" ID="10001551"><Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">ALT </Semaphore><Semaphore x="779631" class="Medicine" value="Level" score="0.87" ID="187620">level </Semaphore>increased </Semaphore>up to 300. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of <Semaphore x="2117785" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Disorder" score="1.00" ID="C3196">hepatic function disorder </Semaphore>was persisting as of an unspecified date. The <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacist </Semaphore>reported that <Semaphore x="2117785" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Disorder" score="1.00" ID="C3196">hepatic function disorder </Semaphore>was related to <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa</Semaphore>. The seriousness of <Semaphore x="2117785" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Disorder" score="1.00" ID="C3196">hepatic function disorder </Semaphore>and causality of <Semaphore x="565378" class="Medicine" value="Femara" score="0.87" ID="241615">Femara </Semaphore>were not reported. The <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacist </Semaphore>commented as follows: because <Semaphore x="2117785" class="Disease or Finding" value="Liver and Intrahepatic Bile Duct Disorder" score="1.00" ID="C3196">hepatic function disorder </Semaphore>developed temporarily after the administration of <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa</Semaphore>, it was considered highly possible that <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa </Semaphore>was related to the event. Although the patient received <Semaphore x="565378" class="Medicine" value="Femara" score="0.87" ID="241615">Femara </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>concomitantly, considering the fact that the changes developed after administration of <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa</Semaphore>, <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">Zometa </Semaphore>was more likely to be suspected.Follow up report received on 06 Dec 2012: Patient's <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data and dosage <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">regimen </Semaphore>of <Semaphore x="1385161" class="Medicine" value="Zometa" score="1.00" ID="242959">zometa </Semaphore>was updated.</narrativeincludeclinical>
				<sendercomment>MAC: Based on the available information, the causative role of the suspect products for the reported event cannot be entirely excluded.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>